45 / 48
Lin J et al. J Clin Oncol 2018
Effect of ALK variants on outcomes to ALK inhibitors
EML4-ALK v3 is associated with a significantly
higher incidence of ALK resistance mutations,
particularly G1202R, and provide a potential
molecular link between variant and clinical
outcome.
Thus, ALK variant status may represent an
important emerging factor in guiding the
treatment strategy for ALK-positive NSCLC.
Crizo 1st line
Crizo 1st line
2nd gen 1st line
Lorlatinib 2nd line